About this data
What it is
The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
Who files it
The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
How current
We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
Terms
openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
Worth knowing
This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
Not to be confused with
Clinical trial updates: what sponsors report about their studies, not what the FDA decided.

All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.

FDA decisions per day, last 30 days

010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0
010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0

Brand-name drugs and biologics, with supplements Device clearances and approvals

By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.

Latest FDA decisions

Showing: since May 19, 2026 (set the dates above to see older items)

Latest FDA decisions
DecidedProductApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.FDA page
Nov 9, 2026—Bayer HealthcareNew drug (NDA)
Type 1 - New Molecular Entity
NDA221291 ↗
Nov 9, 2026OXDERYS
DOXORUBICIN HYDROCHLORIDE
Avyxa HoldingsNew drug (NDA)
Type 5 - New Formulation or New Manufac…
NDA221093 ↗
Nov 9, 2026MULTIBIC
MULTIBIC
Fresenius Medical Care Renal Therapies Group LLCNew drug (NDA)
Type 2 - New Active Ingredient
NDA219457 ↗
Oct 29, 2026AXYCIS
CISPLATIN
Avyxa Holdings, LLCNew drug (NDA)
Type 5 - New Formulation or New Manufac…
NDA220748 ↗
Oct 27, 2026LUCAMZI
RANIBIZUMAB-BLRZ
Xbrane Biopharma ABBiologic (BLA)
Type 2 - New Active Ingredient
BLA761187 ↗
Oct 22, 2026ENZEEVU
AFLIBERCEPT-ABZV
Sandoz IncBiologic (BLA)
UNKNOWN
BLA761382 ↗
Oct 22, 2026AHZANTIVE
AFLIBERCEPT-MRBB
Formycon AGBiologic (BLA)
Type 3 - New Dosage Form
BLA761378 ↗
Oct 22, 2026PAVBLU
AFLIBERCEPT-AYYH
AMGN
Amgen Inc
Biologic (BLA)
UNKNOWN
BLA761298 ↗
Oct 20, 2026HIBSAGO
BEPIROVIRSEN
GSK
Glaxosmithkline LLC
New drug (NDA)
Type 1 - New Molecular Entity
NDA221276 ↗
Oct 19, 2026CALREZDY
CALCUIM CHLORIDE
FMS
Fresenius Medcl Care
New drug (NDA)
Type 2 - New Active Ingredient
NDA219456 ↗
Oct 19, 2026CIENBY
SODIUM CTIRATE
FMS
Fresenius Medcl Care
New drug (NDA)
Type 2 - New Active Ingredient
NDA219455 ↗
Oct 16, 2026YULZETY
RIVAROXABAN
Rosemont PharmaceuticalsNew drug (NDA)
Type 3 - New Dosage Form
NDA221033 ↗
Oct 16, 2026BRYTLY
APRACLONIDINE HYDROCHLORIDE
ALC
Alcon Labs Inc
New drug (NDA)
Type 5 - New Formulation or New Manufac…
NDA220341 ↗
Oct 15, 2026EVOXAC
CEVIMELINE HYDROCHLORIDE
CosetteNew drug (NDA)
Type 3 - New Dosage Form
NDA221183 ↗
Oct 9, 2026HOVILPRI
PRITELIVIR MESYLATE
Aicuris Anti-InfectNew drug (NDA)
Type 1 - New Molecular Entity
NDA221154 ↗
Oct 9, 2026ISOVUE READI
IOPAMIDOL
BraccoNew drug (NDA)
Type 5 - New Formulation or New Manufac…
NDA220583 ↗
Oct 8, 2026BREZTRI AEROSPHERE
BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE
AZN
Astrazeneca AB
New drug (NDA)
Type 5 - New Formulation or New Manufac…
NDA220290 ↗
Oct 8, 2026WELTRUZA
OLANZAPINE
TEVA
Teva
New drug (NDA)
Type 5 - New Formulation or New Manufac…
NDA219007 ↗
Oct 1, 2026TRABECTEDIN
TRABECTEDIN
EverNew drug (NDA)
Type 5 - New Formulation or New Manufac…
NDA219617 ↗
Sep 28, 2026EMCITATE
TIRATRICOL
Rare ThyroidNew drug (NDA)
Type 1 - New Molecular Entity
NDA220963 ↗
Sep 25, 2026ATEBRIOZ
ZILURGISERTIB FUMARATE
MirumNew drug (NDA)
Type 1 - New Molecular Entity
NDA221198 ↗
Sep 25, 2026LAMLIQUE
LAMOTRIGINE HEMIFUMARATE
AzurityNew drug (NDA)
Type 2 - New Active Ingredient
NDA221109 ↗
Sep 25, 2026JUVMO
TAVAPADON
ABBV
Abbvie
New drug (NDA)
Type 1 - New Molecular Entity
NDA220415 ↗
Sep 25, 2026ZUEINO
DICLOFENAC SODIUM
AdventapharmaNew drug (NDA)
Type 5 - New Formulation or New Manufac…
NDA218379 ↗
Sep 25, 2026DEGEVMA
DENOSUMAB-ADET
TEVA
Teva Pharmaceuticals, Inc.
Biologic (BLA)
Type 5 - New Formulation or New Manufac…
BLA761481 ↗
Sep 23, 2026LYRFIGTU
LIRAFUGRATINIB HYDROCHLORIDE
ElevarNew drug (NDA)
Type 1 - New Molecular Entity
NDA220425 ↗
Sep 23, 2026ONSWIK
INSULIN EFSITORA ALFA-GOBE
LLY
Eli Lilly and Co
Biologic (BLA)
Type 1 - New Molecular Entity
BLA761408 ↗
Sep 22, 2026CARBON DIOXIDE, USP
CARBON DIOXIDE, USP
Agl Welding Supply Co Inc Dba Agl Gas TechnologiesNew drug (NDA)
UNKNOWN
NDA222000 ↗
Sep 15, 2026GARZULYS, INSULIN DILUTING MEDIUM FOR GARZULYS
INSULIN ASPART-FSAN
Emerge Bioscience Pte. Ltd.Biologic (BLA)
UNKNOWN
BLA761497 ↗
Sep 14, 2026BEXLUTRY
LUTETIUM LU-177 DOTATATE
CuriumNew drug (NDA)
Type 5 - New Formulation or New Manufac…
NDA218525 ↗
Sep 11, 2026PIXCLARA
FLORETYROSINE F-18
TelixNew drug (NDA)
Type 1 - New Molecular Entity
NDA218592 ↗
Sep 11, 2026ISEMBYLD
APITEGROMAB-MSTN
SRRK
Scholar Rock Inc
Biologic (BLA)
Type 1 - New Molecular Entity
BLA761463 ↗
Sep 4, 2026ETCAMAH
CAMIZESTRANT
AZN
Astrazeneca
New drug (NDA)
Type 1 - New Molecular Entity
NDA220359 ↗
Sep 3, 2026OMCAZIO
CABOZANTINIB LAURYLSULFATE
Handa OncolNew drug (NDA)
Type 5 - New Formulation or New Manufac…
NDA220613 ↗
Sep 3, 2026ZANVASTRO
ZILGANERSEN SODIUM
Ionis Pharmaceuticals IncNew drug (NDA)
Type 1 - New Molecular Entity
NDA220210 ↗
Aug 28, 2026MIMRYLO
RUSFERTIDE ACETATE
TAK
Takeda Pharmaceuticals Am
New drug (NDA)
Type 1 - New Molecular Entity
NDA220605 ↗
Aug 27, 2026BIXLENVO SUNLENCA STARTER PACK (COPACKAGED)
BICTEGRAVIR SODIUM, LENACAPAVIR SODIUM; LENACAPAVIR SODIUM
GILD
Gilead Sciences Inc
New drug (NDA)
Type 4 - New Combination
NDA221443 ↗
Aug 27, 2026BIXLENVO
BICTEGRAVIR SODIUM; LENACAPAVIR SODIUM
GILD
Gilead Sciences Inc
New drug (NDA)
Type 4 - New Combination
NDA221104 ↗
Aug 27, 2026LISRAYA
BREPOCITINIB TOSYLATE
Priovant TherapNew drug (NDA)
Type 1 - New Molecular Entity
NDA220106 ↗
Aug 26, 2026RASONQUE
DARAXONRASIB
RVMD
Revolution Medicines
New drug (NDA)
Type 1 - New Molecular Entity
NDA220910 ↗
Aug 26, 2026VOBRIG
LEUPROLIDE ACETATE
Sun PharmNew drug (NDA)
Type 5 - New Formulation or New Manufac…
NDA213225 ↗
Aug 19, 2026PASATRU
GARETOSMAB-GRTS
REGN
Regeneron Pharmaceuticals, Inc
Biologic (BLA)
Type 1 - New Molecular Entity
BLA761508 ↗
Aug 14, 2026SODIUM BICARBONATE
SODIUM BICARBONATE
BAX
Baxter Hlthcare Corp
New drug (NDA)
Type 5 - New Formulation or New Manufac…
NDA218524 ↗
Aug 13, 2026ZENBEXUS
IBERDOMIDE HYDROCHLORIDE
BMY
Bristol Myers Squibb
New drug (NDA)
Type 1 - New Molecular Entity
NDA221075 ↗
Aug 13, 2026TAUKLARIFY
FLORQUINITAU F-18
Cerveau LantheusNew drug (NDA)
Type 1 - New Molecular Entity
NDA220496 ↗
Aug 9, 2026NITROUS OXIDE, USP
NITROUS OXIDE
Linde Gas EquipNew drug (NDA)
UNKNOWN
NDA221892 ↗
Aug 5, 2026ORZEYFUL
OVEPOREXTON
TAK
Takeda Pharmaceuticals USA
New drug (NDA)
Type 1 - New Molecular Entity
NDA220860 ↗
Jul 31, 2026ZIMRIXBY
RITUXIMAB-CDXX
Dr Reddys Labs SABiologic (BLA)
UNKNOWN
BLA761376 ↗
Jul 29, 2026QLONILIK
CLONIDINE HYDROCHLORIDE
CMP Dev LLCNew drug (NDA)
Type 5 - New Formulation or New Manufac…
NDA221094 ↗
Jul 29, 2026GLYCOPHOS
SODIUM GLYCEROPHOSPHATE
Fresenius Kabi USANew drug (NDA)
Type 2 - New Active Ingredient
NDA220381 ↗

The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 2:59 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates